EpiAxis Therapeutics is pursuing a preclinical and clinical drug development program directed at the prevention of metastatic disease by targeting the pivotal enzyme system controlling the proliferation of cancer stem cells (CSC). Specifically, that target is the nuclear bound lysine-specific demethylase 1 (LSD1) & its upstream regulator, the theta isoform of protein kinase C (PKC theta). The research identifying this target and the intellectual property (IP) that resulted from this was developed by Professor Sudha Rao and colleagues at the University of Canberra (UC), Australia. The Company is focused initially on the prevention of metastatic breast cancer, with other CSC mediated diseases such as ovarian, pancreatic, colon, melanoma, lung and liver cancers to be pursued later. EpiAxis is positioning itself to become the leading cancer recurrence prevention company with its proprietary LSD1 & PKC theta inhibitors included in the standard of care (SoC) for cancer.
There is a substantial unmet clinical need when it comes to fighting recurrent, metastatic breast cancer. This is the major cause of death in women with breast cancer. We aim to address that unmet need by the novel targeting of breast cancer stem cells, which are resistant to conventional systemic anticancer therapies and therefore contribute to the failure of these therapies in patients.
Professor Sudha Rao
Founder & Director at EpiAxis Therapeutics